/CRIS

CRIS Stock - Curis, Inc.

Q: What is the analyst price target for CRIS?

Analyst price target information is not currently available for CRIS.

Q: What is CRIS's market cap?

Market capitalization information is not currently available for CRIS.

Healthcare|Biotechnology|NASDAQ

$1.07-6.96%

$0.08 (-6.96%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

SELL

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $1.18

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for CRIS

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta4.01

52W High$4.50

52W Low$1.02

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$10.91M	$10.02M	$10.16M	$10.65M	$10.84M
Gross Profit	$10.81M	$9.81M	$9.90M	$10.12M	$10.30M
Gross Margin	99.1%	97.9%	97.5%	95.0%	95.1%
Operating Income	$-44,542,000	$-48,332,000	$-53,020,000	$-42,065,000	$-24,898,000
Net Income	$-43,389,000	$-47,413,000	$-56,672,000	$-45,436,000	$-29,908,000
Net Margin	-397.8%	-473.0%	-557.7%	-426.7%	-276.0%
EPS	$-6.88	$-8.96	$-12.14	$-9.92	$-12.29

Company Overview

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

100%

Hold / Neutral

Sell / Underperform

Analyst Consensus🟢 Bullish

2 Bullish0 Neutral/Bearish

Price Targets

$22

Average Target

↑ 1909.3% Upside

Now

$17

Low

$22

Average

$26

High

Based on 2 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
May 19th 2025	H.C. Wainwright	Resumed	Buy	$17
November 17th 2023	Truist	Initiation	Buy	$26

Earnings History & Surprises

CRIS

Beat Rate

41%

Last 17 quarters

Avg Surprise

+3.4%

EPS vs Estimate

Beats / Misses

7/8

2 met exactly

Latest EPS

$-0.49

Q4 2025

EPS Surprise History

Q1 24

-6.3%

$-2.03vs$-1.91

Q2 24

-5.7%

$-2.05vs$-1.94

Q3 24

-19.4%

$-2.03vs$-1.70

Q4 24

+9.6%

$-1.70vs$-1.88

Q1 25

+8.1%

$-1.25vs$-1.36

Q2 25

-9.6%

$-1.25vs$-1.14

Q3 25

+65.8%

$-0.68vs$-1.99

Q4 25

+21.0%

$-0.49vs$-0.62

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Mar 30, 2026	$-0.59	—	—	—
Q1 2026	Feb 4, 2026	$-0.43	—	—	—
Q4 2025	Nov 6, 2025	$-0.62	$-0.49	+21.0%	✓ BEAT
Q3 2025	Aug 5, 2025	$-1.99	$-0.68	+65.8%	✓ BEAT
Q2 2025	May 6, 2025	$-1.14	$-1.25	-9.6%	✗ MISS
Q1 2025	Mar 31, 2025	$-1.36	$-1.25	+8.1%	✓ BEAT
Q4 2024	Nov 14, 2024	$-1.88	$-1.70	+9.6%	✓ BEAT
Q3 2024	Aug 1, 2024	$-1.70	$-2.03	-19.4%	✗ MISS
Q2 2024	May 7, 2024	$-1.94	$-2.05	-5.7%	✗ MISS
Q1 2024	Feb 8, 2024	$-1.91	$-2.03	-6.3%	✗ MISS
Q4 2023	Dec 21, 2023	—	$-2.58	—	—
Q4 2023	Nov 2, 2023	$-2.32	$-2.13	+8.2%	✓ BEAT
Q3 2023	Aug 3, 2023	$-2.40	$-2.40	0.0%	= MET
Q2 2023	May 4, 2023	$-2.20	$-2.40	-9.1%	✗ MISS
Q4 2022	Nov 9, 2022	$-3.40	$-2.80	+17.6%	✓ BEAT
Q3 2022	Aug 4, 2022	$-3.40	$-3.40	0.0%	= MET
Q2 2022	May 5, 2022	$-3.40	$-3.60	-5.9%	✗ MISS
Q1 2022	Feb 24, 2022	$-2.60	$-3.00	-15.4%	✗ MISS
Q4 2021	Nov 9, 2021	$-2.60	$-2.40	+7.7%	✓ BEAT
Q3 2021	Aug 3, 2021	$-2.20	$-2.40	-9.1%	✗ MISS